Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression.
about
Human breast cancer tissues contain abundant phosphatidylcholine(36∶1) with high stearoyl-CoA desaturase-1 expressionLipid metabolic reprogramming in cancer cellsUnderstanding Metabolomics in Biomedical ResearchStructure and function of biotin-dependent carboxylasesApplications of mass spectrometry for cellular lipid analysisObesity and psychotic disorders: uncovering common mechanisms through metabolomicsOn the future of mass-spectrometry-based lipidomicsKey Players in Choline Metabolic Reprograming in Triple-Negative Breast CancerCirculating Phospholipids as Biomarkers of Breast Cancer: A ReviewAdvances in Lipidomics for Cancer Biomarkers DiscoveryA systematic comparison of copy number alterations in four types of female cancerStatin use and breast cancer survival: a nationwide cohort study from FinlandHighly Selective Anti-Cancer Activity of Cholesterol-Interacting Agents Methyl-β-Cyclodextrin and Ostreolysin A/Pleurotolysin B Protein Complex on Urothelial Cancer CellsApplication of desorption electrospray ionization mass spectrometry imaging in breast cancer margin analysisAssessing the barriers to image-guided drug delivery.Stronger findings from mass spectral data through multi-peak modelingRapid evaporative ionisation mass spectrometry of electrosurgical vapours for the identification of breast pathology: towards an intelligent knife for breast cancer surgeryDetermination of lipidomic differences between human breast cancer and surrounding normal tissues using HILIC-HPLC/ESI-MS and multivariate data analysis.Correlation of lipidomic composition of cell lines and tissues of breast cancer patients using hydrophilic interaction liquid chromatography/electrospray ionization mass spectrometry and multivariate data analysis.Low C24-OH and C22-OH sulfatides in human renal cell carcinoma.MACC1 decreases the chemosensitivity of gastric cancer cells to oxaliplatin by regulating FASN expression.Serum Metabolomic Profiles for Breast Cancer Diagnosis, Grading and Staging by Gas Chromatography-Mass Spectrometry.Radiotherapy improves serum fatty acids and lipid profile in breast cancer.Novel nuclear localization of fatty acid synthase correlates with prostate cancer aggressivenessSignificantly increased monounsaturated lipids relative to polyunsaturated lipids in six types of cancer microenvironment are observed by mass spectrometry imaging.Protein and lipid MALDI profiles classify breast cancers according to the intrinsic subtype.Impact of contralateral and ipsilateral reference tissue selection on self-referencing differential spectroscopy for breast cancer detection.Rapid, non-targeted discovery of biochemical transformation and biomarker candidates in oncovirus-infected cell lines using LAESI mass spectrometry.Allele-specific disparity in breast cancer.A joint analysis of metabolomics and genetics of breast cancer.Mass spectrometry-based quantitative metabolomics revealed a distinct lipid profile in breast cancer patients.Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue - a GC-TOFMS based metabolomics study.The lipid phenotype of breast cancer cells characterized by Raman microspectroscopy: towards a stratification of malignancyTargeting cholesterol synthesis increases chemoimmuno-sensitivity in chronic lymphocytic leukemia cells.High-resolution imaging mass spectrometry reveals detailed spatial distribution of phosphatidylinositols in human breast cancer.Phospholipid makeup of the breast adipose tissue is impacted by obesity and mammary cancer in the mouse: Results of a pilot studyAcetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stressPersistent organic pollutants and obesity: are they potential mechanisms for breast cancer promotion?Differential expression of lipid metabolism-related proteins in different breast cancer subtypes.Tissue imaging and serum lipidomic profiling for screening potential biomarkers of thyroid tumors by matrix-assisted laser desorption/ionization-Fourier transform ion cyclotron resonance mass spectrometry.
P2860
Q21090768-23CA5D23-A63D-411E-B03C-4462ACAC9286Q26774859-FDEEF91B-9958-4946-BD42-D2314A42D83AQ26775206-6E5EC830-DB1A-4054-A41F-6DA8F140AA89Q26851762-BE0DB9FF-6EB2-4BE4-8FB1-5A66D22C8956Q26996187-B5BAB00A-21CD-4F7D-830B-607553CFD859Q27011617-B73E4C7D-BB78-4C3D-9E60-581468671D3CQ27012927-3122C08E-C88F-444D-AB82-1AB28DE67CB4Q28074613-D8DBBD0C-ED14-43A4-9921-1A606C553BD8Q28075134-2EE29B1B-446E-4714-8C19-B9EB87E2DD3FQ28079507-37774FC0-77B0-4054-ABB1-2706C6D6DA49Q28394747-65B2732A-0FED-4BE7-BFAB-EC475936EFE7Q28543933-024916BC-AC84-4D6D-8B3B-7E2DF85D6B0DQ28547884-08FE4786-F19F-4530-A661-8DAE77A81807Q30414017-0A1D8C8D-76D6-4C3B-9053-D952C0A23EDFQ30422169-B122D7BE-E039-4E30-BA39-9EAC688D411CQ30832284-0BAD5141-78BE-4F75-AF36-793C6337DD6DQ30853123-24075BFD-3290-4E3D-9901-137ECC5A82AAQ30865106-7C916D29-C280-4980-A7EA-61D9171E346AQ31143237-36E67F3C-F755-4383-853C-B568944D10FFQ31160691-2C99F976-3B51-4468-B168-92560AFE3AFDQ33673940-5FDBCE04-7039-4B4F-B960-F04CBA00A636Q33687106-D2889FE2-B0C9-4321-B1D4-15AAFFB47B6EQ33706437-6C359984-0909-41C5-85E2-533F8C63F770Q33978062-F166AD9C-5A29-4D47-A2F1-772AA0F5A068Q34001479-7D774995-EFCD-4811-944B-2DF49A9F6A5BQ34059226-DA3461ED-6EA1-485F-8D9E-9BA3BDCF891FQ34082185-724C9214-6DB2-4BB0-9E0A-7A4E341BF05BQ34100300-A28B5114-8B51-425B-B8C1-9B2FF1DA5EC5Q34107750-AB9F5B71-B118-45ED-8AF1-491369B5CED8Q34296486-9E673657-B35C-4B09-BB25-04A0EFB84D57Q34339067-284CA131-DD98-4027-859D-F610B8DA6FA1Q34348061-A6D4C31B-8E02-4EE0-8BEE-C9C369D478B9Q34451892-8D3EAD3B-73D4-40FE-B0BE-835C64017860Q34507114-8F8CACCD-29AE-478B-8C6E-3B6EF74E44E3Q34803382-0494EF9E-5733-4A2C-B579-D3A2EE57F499Q34955308-7B45ABE8-A993-4670-9B8C-A149EF790FD1Q34978574-41FAFAB2-C91D-4EAD-B8B0-D1DF84E4F45EQ35154969-B8044E53-9F4E-44B7-A01B-93468BF68EA5Q35159467-D8D9BA37-71E2-4447-9001-2B65B46EAA2CQ35171220-CD3DF719-3C91-40EB-86CB-D81C484EE341
P2860
Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Novel theranostic opportunitie ...... in breast cancer progression.
@en
Novel theranostic opportunitie ...... in breast cancer progression.
@nl
type
label
Novel theranostic opportunitie ...... in breast cancer progression.
@en
Novel theranostic opportunitie ...... in breast cancer progression.
@nl
prefLabel
Novel theranostic opportunitie ...... in breast cancer progression.
@en
Novel theranostic opportunitie ...... in breast cancer progression.
@nl
P2093
P50
P1433
P1476
Novel theranostic opportunitie ...... in breast cancer progression.
@en
P2093
Berit Müller
Christiane Richter-Ehrenstein
Cornelia Radke
Emilia Berg
Heli Nygren
Jan Budczies
Kristiina Iljin
Laura Lehtinen
Laxman Yetukuri
Marko Sysi-Aho
P304
P356
10.1158/0008-5472.CAN-10-3894
P407
P50
P577
2011-03-17T00:00:00Z